Leerink Partners Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $19
Tango Therapeutics: A Buy Rating on PRMT5 Inhibitor Prospects and Upcoming Clinical Data
12 Health Care Stocks Moving In Thursday's After-Market Session
We Think Tango Therapeutics (NASDAQ:TNGX) Can Afford To Drive Business Growth
Third Rock Ventures Sells Shares in Tango Therapeutics Worth Over $700k
Bitcoin Miner Bitfarms, Frontier Communications, and More Stocks See Action From Activist Investors -- Barrons.com
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
H.C. Wainwright analyst Robert Burns maintains $Tango Therapeutics(TNGX.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 26.9
Tango Therapeutics: A Buy Rating Amidst Competitive Advantages and Promising Market Valuation
Small U.S. Stocks Finish Mixed As Xencor Lead, Tango Therapeutics Lags
Piper Sandler Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $18
Piper Sandler analyst Joseph Catanzaro maintains $Tango Therapeutics(TNGX.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 44
Barclays Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Barclays analyst Peter Lawson maintains $Tango Therapeutics(TNGX.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 41.7% and
Barclays Issues a Buy Rating on Tango Therapeutics (TNGX)
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Shares Climb 29% But Its Business Is Yet to Catch Up
Tango Therapeutics to Participate in Upcoming Investor Conferences
Express News | Tango Therapeutics Inc : Guggenheim Raises Target Price to $18 From $14
Multiple Insiders Sold Tango Therapeutics Shares Presenting Weak Signs For Investors
Tango Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)
Tango Therapeutics Analyst Ratings